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High endothelial venules are rare in colorectal
cancers but accumulate in extra-tumoral areas
with disease progression
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Prolonged patient survival after surgical resection, is associated with a higher cytotoxic and memory T cell density
within colorectal cancers (CRC). High endothelial venules (HEVs) are specialized blood vessels present in secondary
lymphoid organs (SLO) that allow ingress of na€ıve and central memory T cells from the blood. It has been proposed that
HEVs in tumors might serve as a similar route of entry for lymphocytes into the tumor and result in an improved
prognosis. The present study aimed to characterize HEVs and their microenvironment in resected tumors from
colorectal cancer patients (n D 62). We observed HEVs in association with lymphoid aggregates in 49 out of 62 patients.
However, these HEVC lymphoid aggregates were largely at the invasive margin of the tumor and although there was an
association with lymphocytes and HEVs at the invasive margin (p D 0.002) there was only a very weak association with
tumor inﬁltrating lymphocytes. Indeed, lymphoid aggregates were associated with more advanced disease (Dukes’
stage C) and did not indicate a favorable prognosis.
Introduction
CRC causes 600,000 deaths annually with 1 million new cases
emerging every year in the Western world.1 Primary tumors are
often removed by surgery, but it remains the case that 40–50%
of patients experience tumor relapse and die of CRC.2 Colec-
tomy specimens are histologically analyzed and the CRC staged
according to an international (TNM) or Dukes’ classification
(Dukes’ stages A–C).3 Patients with tumors confined to the
bowel wall (Dukes’ A) have a > 90% chance of cure while fewer
than half of those with local lymph node metastases (Dukes’ C)
survive more than 5 years post-resection.4 The extent of T cell
infiltration acts as an independent prognostic factor to histopath-
ological staging5-7; thus, it is likely that tumor-infiltrating T cells
may not only play a critical role in limiting disease progression
but also reflect a population of antitumor T cells which can con-
trol disease recurrence after surgical resection.
HEVs are specialized blood vessels usually present in the par-
acortex and interfollicular areas of SLO which allow migration
of L-selectinC cells (e.g. na€ıve and central memory T cells)8
from the blood into the lymphoid organ.9 HEV comprise
cuboidal endothelial cells and express on their surface peripheral
node addressins (PNAds, detected via the well characterized
MECA-79 antibody)10 which act as ligands for L-selectin bind-
ing. Also, the presence of dendritic cells appears to be crucial
for the maintenance of the HEV phenotype.11 Neogenesis of
HEVs has been reported under conditions of chronic inflamma-
tion often in association with de novo formation of tertiary lym-
phoid organs (TLO) comprising a cellular network of B and T
cells.9,12 Recently, the presence of HEVs in lymphocytic rich
areas has been reported in breast, lung, colon, and ovarian carci-
nomas and in melanomas.13–16 According to the more detailed
studies of breast cancer and melanoma, elevated HEV numbers
in the tumor correlates with a better patient outcome and a lon-
ger tumor and metastasis-free survival,13,14 leading the authors
to propose that HEV neogenesis facilitates entry of effector anti-
tumor lymphocytes into the tumor site. In addition, we have
previously shown in mice that control of methylcholanthrene
(MCA)-induced tumors after regulatory T cell (Treg) depletion
was dependent on high densities of T cells within the tumor
microenvironment and was associated with the presence of
HEVs.17
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We have previously examined in detail the phenotype of TILs
in CRCs derived from patients with various stages (Dukes’ A–C)
of disease.18–20 However, although the lymphocyte cellularity of
tumors varies markedly, the mechanism of this remains unclear.
On the basis of our murine studies17 and preliminary data relat-
ing to TILs in CRC, we re-examined tissue sections to ascertain
whether HEVs were present and associated with TIL density.
Specifically, the study was designed to assess whether the presence
or absence of HEVs was associated with (i) the formation of lym-
phoid structures at the site of the CRC, (ii) the number of T cells
present within the tumor mass, (iii) the clinical stage of disease,
and (iv) clinical outcome.
Results
Human colorectal cancers are associated with development
of extra-tumoral but rarely intra-tumoral HEVs
We first sought to determine whether HEVs are present in
normal and/or malignant colon. HEVs were identified through
their characteristic cuboidal and plump morphology, MECA-79
staining, and co-expression of the pan-endothelial cell marker,
CD31 (Figs. 1a–c). No HEVs were detected in normal colon
other than in the context of gut-associated lymphoid tissue
(GALT) (Fig. 1d and Fig. S1). Striking differences were observed
in CRCs where HEVs were often observed in the extra-tumoral
area, positioned ahead of the tumor invasive margin (Figs. 1e
and f). In this extra-tumoral area, highlighted in green in Fig. 1e,
HEVs were always found in association with a concentration of
CD3C T and CD20C B cells (Fig. 1f). HEVs were identified in
the extra-tumoral area of 49 out of 62 patients. Staining with iso-
type control antibodies is shown in Fig. S1.
In contrast to previous reports of breast cancer13 and mela-
noma,14 HEVs were rarely observed within CRC tumor stroma
or epithelium (tumor center). In the small number of tumors
where HEVs were detected within the tumor center (n D 8),
most were atypical due to the flat morphology of the cells
(Fig. 1g) and in some cases absence of lymphocyte aggregates
(Fig. S2).
As reported by others,21 in some cases, the MECA-79 anti-
body also stained the tumor epithelium. This was not indicative
of HEV, as the morphology of the stained cells was clearly not
HEV-like and these structures did not co-express the pan-endo-
thelial marker CD31 indicative of a vessel (data not shown).
HEVs are associated with lymphoid aggregates and
lymphocyte numbers at the tumor invasive margin
HEV-associated lymphocyte clusters observed in the extra-
tumoral area ranged from relatively disorganized lymphoid aggre-
gates comprising collections of T and B cells to organized follicle-
like structures comprising distinct B and T cell areas (Figs. 2a–d).
Lymphoid aggregates represented the majority of lymphocyte
clusters while lymphoid follicles were rarely observed (3.4%).
Overall, there was a highly significant correlation between these
lymphoid structures and HEV density in the extra-tumoral areas
(Fig. 2e: p < 0.0001, R2 D 0.442). The occurrence of HEVs
within the tumor center (tumor epithelium and stroma) was
extremely low (8 out of 62 samples studied), and when the
HEVs were present, there was no significant association with
lymphoid aggregates (Fig. 2f). While all extra-tumoral HEVs
were found in association with lymphocyte aggregates, the recip-
rocal was not the case (data not shown). The inability to detect
HEVs in every lymphocyte aggregate may reflect the 2-dimen-
sional nature of the immunohistochemical analyses rather than
be indicative of aggregates lacking HEVs.
Despite the paucity of HEVs within the tumor itself, a key
question was whether the presence of HEVs and lymphoid aggre-
gates surrounding the tumor reflected an increase in the TIL
number. To determine the impact of these HEVs, total CD3C T
cells were enumerated within the tumor center and the tumor
margin. A significant association was observed between extra-
tumoral HEV density and T cells located within the tumor inva-
sive margin (p D 0.002, R2 D 0.148) but this association was
very weak for the tumor center (p D 0.05, R2 D 0.065) (Fig. 2g).
15% of all CRC are microsatellite instable (MSI)22 and such
tumors are often infiltrated with high numbers of T cells.23 We
therefore examined samples with the highest extra-tumoral HEV
density, including those with HEVs within the tumor center, and
found these to be microsatellite stable (Table S1). To confirm
that MSI does not drive neogenesis of HEV, four MSIC tumors
were subsequently analyzed. No striking differences in HEV den-
sity, distinguishing MSIC and MSI¡ tumors, emerged from this
analysis (data not shown).
Lymphoid aggregates are associated with advanced disease
We next sought to determine whether there was a relationship
between the presence of HEVs and/or lymphoid aggregates (pres-
ent within the extra-tumoral area) and disease progression. As
shown in Fig. 3a, there was no significant difference between
HEV densities and whether a subject had early disease (Dukes’
A: tumor confined to the wall of the bowel) or more advanced
disease (Dukes’ C: spread to adjacent lymph nodes). However,
the presence of lymphoid aggregates/follicles was significantly
associated with more advanced Dukes’ C tumors (Fig. 3b:
Dukes’ A vs. C, p D 0.015. Median number of lymphoid A/ F in
Dukes’ A tumors: 0.025, interquartile range 0.006–0.098.
Median number of lymphoid A/ F in Dukes’ C tumors: 0.085,
interquartile range: 0.039–0.179).
When the relationship between HEVs and T cell infiltration
was assessed with respect to disease stage, we found that the asso-
ciation between extra-tumoral HEVs and T cells present at the
invasive margin, was only significant in patients with Dukes’ C
but not those with Duke’s A disease (Fig. 3c). To determine
whether HEVs were associated with alterations in the composi-
tion as well as the number of T cells in the tumor invasive mar-
gin, sections were stained with antibodies to CD3, CD8C and
FoxP3 and the ratios of CD3C, CD4C (CD3CCD8¡) or CD8C
T cells to FoxP3C T cells were calculated and assessed with
respect to HEV density (Fig. 3d). No significant association was
observed suggesting that extra-tumoral HEVs play no role in
influencing the type of T cells present at the invasive margin in
e974374-2 Volume 4 Issue 3OncoImmunology
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patients that survived 5 years
post-colectomy (Fig. 3e) or
patients that survived less than
5 years (Fig. 3f).
Lymphocytic aggregates are
not associated with patient
prognosis
Since lymphocytic aggregates
were present in the extra-tumoral
areas of individuals with advanced
disease, we determined whether
these were associated with a poor
prognosis. Of the Dukes’ A
tumors analyzed, disease recur-
rence occurred in only three sub-
jects, thus the analysis was
focused in samples from patients
with Dukes’ C tumors. These
were divided according to
whether the patients had suc-
cumbed to disease within 5 years
of colectomy or survived > 5 y.
No significant difference between
the groups was observed when
they were compared for presence
of HEVs (data not shown) or for
numbers of lymphocytic aggre-
gates in the extra-tumoral area
(Fig. 3g). These data imply
that presence or absence of HEV
and/or lymphoid aggregates is not
associated with prognosis in
patients with Dukes’ C tumors.
Discussion
This study focused on the
identification and characterization
of HEVs in CRC. We established
that HEVs form primarily in the
extra-tumoral area and rarely
within the tumor stroma/epithe-
lium. Moreover, these vessels
associate with T and B cells form-
ing aggregates/follicles in agreement with an active role for the
vessels in lymphocyte recruitment.14,16 The density of these fol-
licles/aggregates is associated with advanced disease as signifi-
cantly higher numbers, approximately 3.4X (Dukes’ A median
0.02451, range 0–0.6647; Dukes’ C median 0.08455 range 0–
0.5823) were observed in Dukes’ C compared to Dukes’ A
tumors. While HEVs are found in the GALT of healthy and dis-
eased colon, the HEVs associated with CRC are found more
deeply within the bowel wall. These observations suggest that
CRC results in initiation of a local immune response driving de
novo formation of these structures. The increase in lymphocytic
aggregate/follicle density in Dukes’ C tumors may be indicative
of an intensification of the local immune response corresponding
with tumor progression.
The question that arises from these data is whether HEV and/
or lymphoid aggregates impacts on patient prognosis. In studies
of breast cancer13 and melanoma,14 high densities of tumor
HEVs was associated with an accumulation of T and B cells,
high numbers of tumor-infiltrating lymphocytes and a better
clinical outcome. We found no relationship however, between
Figure 1. Immunohistochemistry staining of MECA-79C and CD31C vessels, CD3C, CD20C cells in parafﬁn-
embedded formalin ﬁxed samples of healthy colon and colorectal tumor. (A) Detail of a HEV in gray (MECA-
79C). Consecutive sections stained with (B) MECA-79 (gray), CD3 (brown), CD20 (pink) and (C) CD-31. (D) Rep-
resentative example of a healthy colon lacking lymphoid A/F. The section was stained with anti-CD3, CD20
and MECA-79. (E) Overview of a colorectal adenocarcinoma. The area highlighted in green illustrates the
extra-tumoral area, surrounding the tumor but not the tumor itself. HEVs were located in the extra-tumoral
area at the advancing tumor invasive margin. (F) Lymphoid aggregates were located ahead of the tumor
edge/tumor invasive margin. The area between the black line and the dashed line indicates where T cells
were enumerated. The distance between these two lines is equivalent to one high power ﬁeld at 600x magni-
ﬁcation. (G) Detail of a lymphoid aggregate/follicle with a HEV within the tumor center. HEV, high endothelial
venule. A/F, lymphoid aggregates/ follicles.
www.tandfonline.com e974374-3OncoImmunology
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lymphoid aggregate densities (and HEVs) with survival of
patients with Dukes’ C tumors, implying that while presence of
large numbers of these structures reflects advanced disease they
are not associated with a favorable prognosis. Indeed, we
observed trends for high numbers of lymphoid aggregates in
patients who did not survive >5 y post-tumor resection com-
pared to those who did (patients who did not survive >5 post-
tumor resection median 0.1260, range 0–0.5823; patients who
survived >5 y post-tumor resection median 0.0766 range 0–
0.4039) suggesting that the presence of lymphoid aggregates/fol-
licles, albeit within the tumor periphery, do not facilitate an
effective antitumor response in Dukes’ C tumors. Actually, the
data are compatible with the hypothesis that formation of lym-
phoid aggregates within the extra-tumoral area reflects an
immune response driven by the tumor, which may serve to
facilitate cancer progression. Pres-
ence of lymphoid aggregates in
the large intestine have also been
reported in inflammatory bowel
diseases24 and these patients are at
greater risk of developing CRC.25
Thus, in contrast to the findings
in the cancer studies described
above, we have found no positive
prognostic value to the presence
of CRC-driven lymphoid aggre-
gates or HEVs. However, in com-
parison to breast cancer and
melanoma, in CRC HEVs were
rarely observed within the tumor
epithelium/stroma. It is possible
that HEV neogenesis within
CRCs is actively inhibited. We
have previously shown in a mouse
model of carcinogen-induced
fibrosarcomas that HEV forma-
tion within these tumors is depen-
dent on Treg depletion.17 These
data raise the interesting possibil-
ity that Tregs or perhaps other
immunosuppressive mechanisms
present within CRCs act to inhibit
HEV formation limiting the
extent of lymphocyte infiltration
into the tumor.
While only early stage (Dukes’
A) and advanced (Dukes’ C)
tumors were included in our
study, Di Cario et al. recently
reported that lymphoid aggregates
were associated with a favorable
prognosis for Stage II CRCs, but
only for those with no node
involvement.16 A high density of
Crohn’s like reaction has also
been reported to be associated with less advanced disease and
microsatellite instability (MSI).26 These data suggest that ele-
vated frequencies of lymphoid aggregates in mismatch repair
defective tumors, which are thought to be more immunogenic
than microsatellite stable tumors, may be beneficial. Collectively
these data raise the interesting possibility that the composition of
these lymphoid aggregates, and therefore their prognostic signifi-
cance, alters with disease progression and according to the inher-
ent immunogenicity of the tumor. With this in mind, studies to
evaluate T cell activation signals and T cell signatures within
these ectopic structures at different disease stages are warranted.
Collectively, the findings of our study indicate key differences
in the relationship between ectopic lymphoid structures develop-
ing in response to CRC as opposed to those reported in non-
small cell lung27 and breast cancer.13 In the case of the latter
Figure 2. Relationship between lymphoid aggregates, high endothelial venules and T cell inﬁltration at the
invasive margin and the tumor center. (A) Lymphoid aggregate without HEVs. (B) Lymphoid aggregate with
HEVs. (C) Lymphoid follicle without HEVs. (D) Lymphoid follicle with HEVs. (E) Lymphoid A/F density vs. HEV
density in the extra-tumoral area of all tumors (n D 62). (F) Lymphoid A/F density vs. HEV density in the
tumor center. (G) HEV density in the extra-tumoral area vs. CD3 counts at the tumor invasive margin (black)
and in the tumor center (gray) (n D 62). HEV, high endothelial venule. A/F, lymphoid aggregate/ follicle.
HPFV, high power ﬁeld of view. The white dashed lines in (C) and (D) represents organized B cell areas in fol-
licles. p< 0.05 was considered signiﬁcant.
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tumor, HEVs and a concentra-
tion of T and B cells were
found within the tumor stroma
where their density correlated
with the extent of T cell infil-
tration. In our study, HEVs
were rarely found within CRC
tumors’ stroma/epithelium and
we found no relationship
between HEVs in these areas
and the extent of T cell infiltra-
tion at either of the cancer
stages examined. These data
suggest that in CRC, intra-
tumoral HEVs play a minor
role, if any, in recruiting
tumor-infiltrating lymphocytes.
In conclusion, this study of
CRC-associated HEV and lym-
phoid aggregate formation revealed that these structures in fact
rarely form in tumors, but accumulate in locations close to the
tumor invasive margin. These structures form in association with
more advanced tumors, suggesting they are a reaction to progres-
sive tumor invasion.
Materials and Methods
Tissue samples
We have previously studied the phenotype of TILs in 62
tumor samples (and adjacent healthy bowel) from patients who
Figure 3. Lymphoid aggregate/
follicle density is a marker of dis-
ease progression but not survival.
(A) HEV density in the extra-
tumoral area in Dukes’ A and C
cases. (B) Density of lymphoid
aggregates/follicles in the extra-
tumoral area in Dukes’ A and C
cases. (C) CD3 counts per 10 HPFV
at the tumor invasive margin vs.
HEV density in the extra-tumoral
area for Dukes’ A (black) and C
(gray). (D) The median density in
the extra-tumoral area was used
to categorize cases into HEV low
and HEV high. T cell ratios at the
advancing margin of HEV low and
high tumors in: (E) patients who
survived 5 yeras post-colectomy
and (F) patients that survived less
than 5 yeras post-surgery. Con-
ventional T cells (Tcon) were con-
sidered to be CD4C and CD8C T
cells combined excluding FoxP3C
T cells. (G) Lymphoid aggregate/
follicle density in the extra-
tumoral area for Dukes’ C patients
who survived for more or less
than 5 yeras post-colectomy. The
median value with the interquar-
tile range is shown for (A), (B), (E),
(F) and (G). HEV, high endothelial
venule, A/F, lymphoid aggre-
gates/follicles. Hpfv, high power
ﬁeld of view. p< 0.05 was consid-
ered signiﬁcant.
www.tandfonline.com e974374-5OncoImmunology
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have undergone a colectomy for known Dukes’ A and C CRC.
Patient’s age, gender, tumor location, tumor Dukes’ staging and
5 year survival was also obtained (Table S2). Local research ethics
committee approval was obtained to perform histological analy-
ses of tumor samples in order to explore the extent to which they
are infiltrated with lymphocytes.
Immunohistochemistry
5 mm thick sections were cut with a microtome (Surgipath),
mounted, hydrated in xylene before immersion in descending
alcohol concentrations and distilled water. Antigen retrieval was
performed when necessary (Table S3). Slides were washed in
phosphate buffered saline (PBS), immersed in 1% hydrogen per-
oxide diluted in methanol (1% H2O2/MeOH) for 10 min and
washed with PBS. Unspecific binding was blocked with either
2.5% of normal horse or goat serum (Vector laboratories) added
for 30 min. The primary antibody was diluted in 1% bovine
serum albumin (BSA) in PBS and incubated overnight at 4C in
a humid chamber (Table S3) followed by washing in PBS then
incubating with Impress secondary antibody (Vector laborato-
ries) for 30 min. Impress anti-Rabbit, anti-Rat or anti-Mouse
was used depending on the species of the primary antibody.
Vector chromagen DAB, SG or VIP was used to visualize anti-
body complexes. Slides were mounted in DPX and left drying
overnight at 65C. Isotype control antibodies were used at the
same concentrations and conditions.
Cell quantification
CD3C, CD4C (CD3CCD8¡), CD8C, and FoxP3C labeled
cells were enumerated on a NIKON microscope by averaging the
cell counts from 10 high power (600x) fields of view within both
the tumor mass and by the tumor invasive margin.
Sequential sections were scanned with a scanscope (Aperio
technologies) and the HEV and aggregate/ lymphocyte analysis
performed with ImageScope viewer software (Aperio). HEV den-
sity was calculated either by enumerating all the HEVs within
the tumor center and dividing it by the corresponding area (in
mm2), or by enumerating all the HEVs within the extra-tumoral
area and dividing by the respective area in mm2 so that two
regions of the tumor environment were evaluated. In addition,
lymphocyte aggregates/follicles composed of B and T cells were
enumerated within the extra-tumoral area and the lymphocyte
aggregate/follicle density obtained by dividing the number of
aggregates/follicles by the extra-tumoral area in mm2. GALT as
part of the normal bowel was excluded from the lymphocyte
aggregate/follicle enumeration.
Microsatellite instability analysis
Tumor tissue from samples containing HEVs within the
tumor center and from samples with the highest HEV density
within the extra-tumoral area (for both Dukes’ A and C) was col-
lected and incubated for 1 h at 57C in the presence of ATL
buffer (QIAGEN) and proteinase K followed by a 1 h incubation
at 90C. The EZ1 DNA Tissue kit (QIAGEN) was used with the
EZ1 Advanced XL robot (QIAGEN) according to the man-
ufacturer’s instructions to purify DNA. The MSI Analysis System
(Promega) was used to identify MSI according to the man-
ufacturer’s instructions. Following PCR, the 3730 DNA Ana-
lyzer (Applied Biosystems) was used to perform capillary
electrophoresis. Peak ScannerTM Software Version 1.0 (Applied
Biosystems) was used for analysis. For a sample to be considered
MSI at least 2 out of the 5 microsatellite loci studied had to be
instable.
Statistical analyses
Prism 5 (GraphPad) was used to perform all of the statistical
analyses. The Mann–Whitney statistical test was used for com-
parison among groups. The Pearson method was used for correla-
tion analyses and both p-value and Pearson correlation
coefficients (r2) are shown. A p-value < 0.05 was considered
significant.
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